Article Text

Download PDFPDF

Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Free

Statistics from Altmetric.com

Mandalá M, Larkin J, Ascierto PA, et al. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J ImmunoTher Cancer 2021;9:e003188. doi: 10.1136/jitc-2021-003188.

This article has been corrected since it was first published. Author name has been corrected from 'Ivan Marquez' to 'Ivan Marquez-Rodas'.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.